Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maja Bürdek

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Seminars in Cancer Biology|February 29, 2012
Recent advances on the role of tumor exosomes in immunosuppression and disease progressionPaola Filipazzi, Maja Bürdek, Antonello Villa, et al.
Journal of Translational Medicine|October 6, 2010
Three-day dendritic cells for vaccine development: antigen uptake, processing and presentationMaja Bürdek, Stefani Spranger, Susanne Wilde, et al.
Cancers|January 25, 2025
Characterization of a 3S PRAME VLD-Specific T Cell Receptor and Its Use in Investigational Medicinal Products for TCR-T Therapy of Patients with Myeloid MalignanciesMaja Bürdek, Petra U Prinz, Kathrin Mutze, et al.
Frontiers in Immunology|July 6, 2019
Clonality of CD4<sup>+</sup> Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced MelanomaAkiko Arakawa, Sigrid Vollmer, Julia Tietze, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 2010
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075Stefani Spranger, Miran Javorovic, Maja Bürdek, et al.
Cancers|April 23, 2022
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor ReactivityNadja Sailer, Ina Fetzer, Melanie Salvermoser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2016
TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor SiteLicia Rivoltini, Claudia Chiodoni, Paola Squarcina, et al.
Cancers|September 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid NeoplasmsSimone Thomas, Martin Wermke, Vladan Vučinić, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Seminars in Cancer Biology|February 29, 2012
Recent advances on the role of tumor exosomes in immunosuppression and disease progressionPaola Filipazzi, Maja Bürdek, Antonello Villa, et al.
Journal of Translational Medicine|October 6, 2010
Three-day dendritic cells for vaccine development: antigen uptake, processing and presentationMaja Bürdek, Stefani Spranger, Susanne Wilde, et al.
Cancers|January 25, 2025
Characterization of a 3S PRAME VLD-Specific T Cell Receptor and Its Use in Investigational Medicinal Products for TCR-T Therapy of Patients with Myeloid MalignanciesMaja Bürdek, Petra U Prinz, Kathrin Mutze, et al.
Frontiers in Immunology|July 6, 2019
Clonality of CD4<sup>+</sup> Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced MelanomaAkiko Arakawa, Sigrid Vollmer, Julia Tietze, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 2010
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075Stefani Spranger, Miran Javorovic, Maja Bürdek, et al.
Cancers|April 23, 2022
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor ReactivityNadja Sailer, Ina Fetzer, Melanie Salvermoser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2016
TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor SiteLicia Rivoltini, Claudia Chiodoni, Paola Squarcina, et al.
Cancers|September 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid NeoplasmsSimone Thomas, Martin Wermke, Vladan Vučinić, et al.
Pageof 1